8-K filed May 7, 2026 at 07:10 ET
Ironwood Pharmaceuticals reported a massive Q1 2026 beat with GAAP EPS of $0.24 vs $0.07 consensus (+243%) and revenue of $106.5M, driven by a 97% surge in LINZESS U.S. net sales to $272.5M due to improved net pricing. Full-year 2026 guidance was maintained, with LINZESS net sales expected at $1.125-$1.175B and adjusted EBITDA >$300M. The strong cash generation positions the company for its June convertible note maturity.